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oriGinal report
Alloimmunization to red blood cell antigens is seen in patients 
receiving chronic blood transfusion. Knowing the prevalence of 
blood group antigens of the different ethnicities of South Texas 
donors can provide better management of rare blood inventory 
for patients in this geographical area. A total of 4369 blood donors 
were tested and analyzed for various antigens in the following 
blood group systems: ABO, Rh, Kell, Duffy, Kidd, MNS, Lutheran, 
Dombrock, Landsteiner-Wiener, Diego, Colton, and Scianna. 
Donors tested to be group O or A were serologically tested for 
the Rh (C, E, c, e) antigens. Those that tested as presumably 
R1R1, R2R2, or R0r were then genotyped. Donors constituted 
three major ethnicities: black (18.3%), Hispanic (36.3%), and 
Caucasian (41.1%); ethnicities comprised of Asian, American 
Indian, multiracial, and other accounted for the remaining donors 
(4.3%). The most likely common Rh phenotype for each ethnicity 
is as follows: black –R0r (44.4%), Hispanic –R1R1 (59.0%), and 
Caucasian –R1R1 (38.9%). The prevalence of Kell, Duffy, and Kidd 
blood group system antigens in black and Caucasian donors is 
comparable with published reports for the entire U.S. The black 
South Texas donor population had an 8.8 percent increase in 
prevalence of the Fy(a+b–) phenotype as compared with these 
published reports; the Hispanic South Texas donor population had 
a prevalence of 36.1 percent of the Fy(a+b–) phenotype. Regarding 
the Diego blood group system, the Hispanic donor population in 
South Texas had a prevalence of 93.5 percent for the Di(a–b+) 
phenotype as compared with published reports for the entire U.S. 
(>99.9%). The Hispanic population had a prevalence of 7.9 percent 
of donors testing as M–N+S–s+ as compared with 20.2 percent 
and 15.6 percent for black and Caucasian donors, respectively. 
This study helped us determine the prevalence of each of the blood 
group antigens in the South Texas donor population to establish 
and maintain adequate rare inventory of each. Molecular red 
blood cell genotyping allows transfusion services to increase 
their availability of rare phenotypes for chronically transfused 
patients. Immunohematology 2015;31:166–173.
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Donating blood and blood components can potentially 
save a recipient’s life. Red blood cell (RBC) transfusion can 
also cause alloimmunization, which can lead to shortened RBC 
survival and/or transfusion reactions.1 In the laboratory blood 
bank, routine pretransfusion testing is performed on patient 
samples to mitigate possible immune-mediated hemolytic 
transfusion reactions (HTRs) by observing antigen–antibody 
reactions in vitro before blood is released for transfusion.2 
Despite these procedures, there have been instances when a 
patient has had a transfusion reaction due to the development 
of red blood cell antibodies in the Rh, Kidd, Duffy, Kell, and 
MNS blood group systems.3 Delayed hemolytic transfusion 
reactions (DHTRs) can occur, causing fever and anemia, 
days or weeks after a blood transfusion.3 The risk of RBC 
alloimmunization increases as the number of transfusions 
increase.4 The probability of developing additional antibodies 
to RBC antigens increases for those who have developed 
alloantibodies, especially in non-hemato-oncologic patients.4 
Because of their hemoglobinopathy, patients with sickle 
cell disease (SCD) may be chronically transfused and are at 
higher risk of developing RBC alloantibodies.5 Presently, many 
facilities antigen-match their patients with SCD for Rh (C, E, 
c, e) and Kell (K) to prevent RBC alloimmunization. Extended 
matching for Duffy (Fya, Fyb), Kidd (Jka, Jkb), and MNS (M, N, 
S, s) is rarely performed by facilities.6
The probability of finding specific blood phenotypes 
depends on the prevalence of that phenotype in a population.7 
The purpose of this study was to determine the prevalence of 
various RBC antigens in the blood donor population of South 
Texas. By doing so, an adequate phenotyped blood supply can 
be established and maintained to help manage the needs of 
chronically transfused patients, such as patients with SCD.
Material and Methods
The institutional review board of The George Washington 
University (Washington, DC) and the research committee 
from BioBridge Global (San Antonio, TX) gave approval to 
retrieve pertinent data from volunteer allogeneic blood donors 
collected by the South Texas Blood & Tissue Center (STBTC), 
San Antonio, TX; STBTC collects about 150,000 blood units a 
year and supplies blood products to 67 hospitals in 43 South 
Texas counties. For this study, records from 4369 donors from 
the period of June 2007 to November 2014 were analyzed.
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Random donors were selected at least once a week from 
different blood donor drives in the South Texas area. Each 
of these drives had between 75 to 100 possible whole blood 
donations. Donor samples received all required routine donor 
testing (namely, serological testing to determine ABO and 
D, and unexpected antibodies) and viral marker testing for 
infectious diseases. Informed consent for laboratory testing 
was received at donor registration using the donor history 
questionnaire form. An existing ethylenediaminetetraacetic 
acid (EDTA) blood sample tube collected at the time of 
donation was retrieved for this testing.
These donor samples were tested on the Beckman Coulter 
PK7300 analyzer (Olympus, Center Valley, PA) for ABO and 
D, C (RH2), E (RH3), c (RH4), and e (RH5). Group O and 
A donor samples that serologically tested as D+C+E−c−e+ 
[probable R1R1 (DCe/DCe)], D+C−E+c+e− [probable R2R2 
(DcE/DcE)], or D+C−E−c+e+ [probable R0r (Dce/ce)] with 
the PK7300 were retrieved for molecular testing. In addition, 
donors were randomly selected for molecular testing if they 
met one of three criteria: at least 10 or more blood donations in 
their history, self-designated as black, or D–.
The DNA for the molecular test was extracted from the 
donor sample using the fully automated QIAcube (QIAGEN, 
Valencia, CA). The BioArray HEA BeadChip (HEA 1.1) 
system (Immucor, Norcross, GA) was used from June 2007 
to February 2009 to genotype each selected donor sample for 
multiple human erythrocyte antigens by DNA analysis. The 
BioArray HEA BeadChip (HEA 1.2) system was used for testing 
from March 2009 to November 2014. Genotyping for RBC 
antigens included those in the Rh (C, E, c, e, V, VS), Kell (K, k), 
Duffy (Fya, Fyb), Kidd (Jka, Jkb), MNS (M, N, S, s), Lutheran 
(Lua, Lub), Dombrock (Doa, Dob, Hy, Joa), Landsteiner-Wiener 
(LWa, LWb), Diego (Dia, Dib), Colton (Coa, Cob), and Scianna 
(Sc1, Sc2) blood group systems. The HEA 1.2 version included 
Kpa, Kpb, Jsa, and Jsb antigens of the Kell system.
The PK7300, BioArray, and QIAcube systems were used 
in accordance with manufacturer’s instructions and standard 
operating procedures.
Statistical Analysis
The prevalence of blood types, ethnicities, donor age, 
and the various RBC phenotypes were calculated using 
SPSS Statistics, version 22.0 (IBM Corporation, Armonk, 
NY). Genotype occurrence, antigen-negative phenotype 
calculations, and phenotype prevalence were determined. The 
Hardy–Weinberg equilibrium formula was used to calculate 
genotype occurrence. Antigen-negative phenotype was 
calculated by multiplying the negative prevalence values for 
particular antigens. Phenotype prevalence was calculated as 
a percent, given the total positive results divided by the total 
tested of each antigen in the blood group systems.
Results
Data from 4369 South Texas whole blood donors 
were analyzed in this study. The ethnicity, age, and gender 
percentages were calculated based on information from 
the donation records. Thirty-one donors did not indicate 
their ethnicity, leaving a total of 4338 donors studied. The 
percentage for those donors who indicated their ethnicity is 
as follows: 18.3 percent black, 0.2 percent American Indian 
(AIAN), 1.3 percent Asian/Pacific Islander (ASPI), 41.1 
percent Caucasian (CAUC), 36.3 percent Hispanic (HISP), 1.6 
percent multiracial (MULT), and 0.6 percent other (OTHR; 
unable to determine proper ethnicity due to limitations of 
computer system ethnicity choices).
The mean age of the donors in this study was 42.7 years, 
and the most frequent age was 21 years. The youngest donor 
was 16 years old and the oldest donor was 91 years old. The 
gender distribution of each ethnicity was the following (% 
female/% male): black (50.1/49.9), AIAN (44.4/55.6), ASPI 
(46.4/53.6), CAUC (43.8/56.2), HISP (51.7/48.3), MULT 
(52.2/47.8), and OTHR (42.9/57.1).
 Donors with blood groups A and O were specifically 
selected for this study because these blood groups occur 
most frequently in CAUC (43%, 44%) and black (27%, 49%) 
populations, respectively.8 In addition, group O individuals 
are considered universal donors, since their RBCs are 
ABO-compatible with the plasma of group O, A, B, and AB 
recipients.2 Therefore, the donors for this study were not 
random, but selected; 75.1 percent had blood group O, and 
18.9 percent had blood group A, as shown in Table 1. In 
addition, blood group B and AB donors were 5.4 percent and 
0.6 percent, respectively. The prevalence of D (RH1) in these 
donors was 86.6 percent, as shown in Table 1. These blood 
group percentages are consistent with the algorithm used in 
this study for retrieving samples for genetic testing. There 
were four ethnicities (AIAN, ASPI, MULT, and OTHR) that 
were not included for further analysis in the study, because the 
percentages of these ethnicities were all less than 2.0 percent 
of the total.
Table 2 summarizes the comparison of published per-
centages of black and CAUC phenotypes with those of South 
Texas donors who are black, CAUC, and HISP.8 Donor samples 
that typed as presumably R1R1, R2R2, and R0r were specifically 
retrieved for this study; these types are negative for at least 
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two antigens in the Rh blood group system (C, E, c, e). In the 
black population, the prevalence was 4.0 percent for R1R1 and 
1.7 percent for R2R2 as compared with published phenotype 
prevalence  for this ethnicity of 2.0 percent and 0.2 percent, 
respectively. The CAUC population prevalence for R1R1 was 
38.9 percent and for R2R2 was 6.1 percent, as compared with 
published phenotype prevalence for this ethnicity of 18.5 
percent and 2.3 percent, respectively. The HISP population had 
one of the highest phenotype prevalences observed for R1R1 at 
59.1 percent and for R2R2 at 18.5 percent, as compared with the 
prevalence of published black and CAUC phenotypes. Because 
donor samples with known R1R2 phenotypes were not pulled 
for this study, there was a decrease in these phenotypes for 
black (3.1%) and CAUC (4.3%) populations as compared with 
published reports of 4.0 percent and 13.3 percent, respectively. 
The HISP donor population had a prevalence of 2.0 percent for 
the R1R2 phenotype. 
The prevalence for the phenotype rr (D–C–E–c+e+) was 
observed as the highest within the CAUC population (21.9%), 
followed by the HISP (6.8%) population and finally the black 
population (3.5%), as compared with those published reports 
of black (6.8%) and CAUC (15.1%) populations. The prevalence 
of these selected phenotypes was higher than the published 
phenotype prevalence, due to retrieval of these phenotypes 
for this study. The phenotype prevalence of R1r for the CAUC 
population was 19.9 percent, as compared with published 
reports of 34.9 percent. It is lower in this study because this 
phenotype knowingly was not retrieved for genotyping. 
Table 3 summarizes the prevalence of Kell, Duffy, and Kidd 
phenotypes of South Texas donors who were black, CAUC, 
and HISP, as compared with published black and Caucasian 
reports.8 The black population results were comparable with 
the published phenotypes, with the exception of an increase 
in Kp(a+b+), Fy(a+b–), and Fy(a+b+) phenotypes. The South 
Texas donor prevalence for these phenotypes was 2.3 percent, 
17.8 percent, and 4.5 percent, respectively, as compared with 
published reports of rare, 9 percent, and 1 percent, respectively. 
In addition, a decrease in prevalence was seen with Fy(a–b–) 
Table 1. Prevalence of ABO group and D type in South Texas donors by ethnicity*
Prevalence (%)
Blood group/D type Black AIAN ASPI CAUC HISP MULT OTHR Total
O 65.4 88.9 61.8 72.6 83.6 69.1 71.4 75.1
A 22.6 11.1 21.8 22.7 12.4 26.5 21.4 18.9
B 10.8 0.0 0.0 4.0 3.9 2.9 7.1 5.4
AB 1.3 0.0 0.0 0.7 0.1 1.5 0 0.6
D 95.9 66.7 100 76.9 92.5 89.7 78.6 86.6
*N = 4338; AIAN = American Indian; ASPI = Asian/Pacific Island; CAUC = Caucasian; HISP = Hispanic; MULT = Multiracial; OTHR = Other.
Table 2. Rh blood group phenotype prevalence: comparison of South Texas donors with published reports8
Phenotype Black prevalence (%) CAUC prevalence (%) HISP prevalence (%)
Wiener N = 747* Published reports N = 1785* Published reports N = 1570*
R1R1 4.0 2.0 38.9 18.5 59.0
R2R2 1.7 0.2 6.1 2.3 18.5
R¹r 26.0 21.0 19.9 34.9 7.6
R2r 17.0 18.6 7.5 11.8 2.6
R0r 44.4 45.8 1.3 2.1 2.4
RzRz 0.0 RARE 0.0 0.0 0.1
R1Rz 0.1 RARE 0.1 0.2 0.6
R1R2 3.1 4.0 4.3 13.3 2.0
r´r 0.0 RARE 0.1 0.8 0.0
r´r´ 0.0 RARE 0.1 RARE 0.1
r˝r 0.1 RARE 0.1 0.9 0.2
rr 3.5 6.8 21.9 15.1 6.8
r´r˝ 0.0 RARE 0.0 0.1 0.1
*South Texas donors.
CAUC = Caucasian; HISP = Hispanic.
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(57%) and Jk(a–b+) (5.7%), as compared with published 
prevalence of 68.0 percent and 8.1 percent, respectively. The 
prevalence of the South Texas CAUC donor population for 
Kell, Duffy, and Kidd phenotypes compared with published 
reports. In the HISP population, the Fy(a+b–) phenotype was 
significantly higher at 36.1 percent, as compared with both the 
published prevalence for CAUC and black of 9 percent and 17 
percent, respectively. There was no significant difference in the 
prevalence of Kell, Duffy, and Kidd phenotypes for the HISP 
donor as compared with both the published CAUC and black 
phenotypes. 
Table 4 compares the prevalence of MNS blood group 
antigens in black and CAUC published phenotypes with that of 
black, CAUC, and HISP South Texas donors.8 The prevalence 
of MNS phenotypes in the black population was comparable 
with the published prevalence, except for an increase in 
Table 3. Prevalence of Kell, Duffy, and Kidd blood group phenotypes: comparison of South Texas donors with published reports8
Blood group system Phenotype
Black CAUC HISP
South Texas donors Published reports South Texas donors Published reports South Texas donors
N Prevalence (%) Prevalence (%) N Prevalence (%) Prevalence (%) N Prevalence (%)
Kell K–k+ 779 97.6 98 1633 91.4 91 1529 96.8
K+k+ 18 2.3 2 152 8.5 8.8 51 3.2
K+k– 1 0.1 RARE 2 0.1 0.2 0 0.0
Kp(a+b+) 14 2.3 RARE 29 2.2 2.3 18 1.3
Kp(a–b+) 596 97.7 100 1322 97.9 97.7 1396 98.7
Js(a+b+) 115 18.9 19 4 0.3 RARE 19 1.4
Js(a+b–) 5 0.8 1 1 0.1 0 0 0.0
Js(a–b+) 490 80.3 80 1339 99.6 100 1392 98.7
Duffy Fy(a+b–) 142 17.8 9 350 19.6 17 571 36.1
Fy(a+b+) 36 4.5 1 828 46.3 49 648 41.0
Fy(a–b+) 165 20.7 22 604 33.8 34 350 22.1
Fy(a–b–) 455 57.0 68 6 0.3 RARE 13 0.8
Kidd Jk(a+b–) 424 53.3 51.1 450 25.2 26.3 380 24.0
Jk(a+b+) 327 41.1 40.8 910 50.9 50.3 803 50.8
Jk(a–b+) 45 5.7 8.1 429 24.0 23.4 398 25.2
CAUC = Caucasian; HISP = Hispanic.
Table 4. Prevalence of MNS blood group phenotypes: comparison of South Texas donors with published report8
Blood group system Phenotype
Black CAUC HISP
South Texas donors Published reports South Texas donors Published reports South Texas donors
N Prevalence (%) Prevalence (%) N Prevalence (%) Prevalence (%) N Prevalence (%)
MNS M+N+S+s+ 95 12.2 13 418 23.5 24 338 21.4
M+N+S+s– 24 3.1 2 55 3.1 4 69 4.4
M+N+S–s+ 247 31.6 33 396 22.3 22 331 21.0
M+N+S–s– 5 0.6 0.4 0 0.0 0 0 0.0
M+N–S+s– 19 2.4 2 101 5.7 6 126 8.0
M+N–S+s+ 41 5.3 7 271 15.2 14 311 19.7
M+N–S–s+ 151 19.3 16 173 9.7 8 214 13.6
M+N–S–s– 2 0.3 0.4 0 0.0 0 0 0.0
M–N+S–s+ 158 20.2 19 277 15.6 15 125 7.9
M–N+S–s– 1 0.1 0.7 0 0.0 0 0 0.0
M–N+S+s+ 32 4.1 5 78 4.4 6 57 3.6
M–N+S+s– 6 0.8 2 10 0.6 1 8 0.5
CAUC = Caucasian; HISP = Hispanic.
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the M+N–S–s+ phenotype prevalence of 19.3 percent, as 
compared with the published 16.0 percent. The prevalence of 
MNS phenotypes in the South Texas CAUC donor population 
was comparable with that of published reports. The prevalence 
for the M+N–S+s+ phenotype in the HISP population was 
19.7 percent, as compared with published CAUC and black 
phenotypes of 14.0 percent and 7.0 percent, respectively. In 
addition, the prevalence of the phenotype M–N+S–s+ in the 
HISP population was 7.9 percent, as compared with CAUC 
and black phenotypes of 15.0 percent and 19.0 percent, 
respectively. 
Table 5 includes those blood group systems that contain 
high- and low-prevalence antigens. The prevalence of the Colton 
blood group system phenotype Co(a+b+) was 3.3 percent in 
the black population, 2.9 percent in the HISP population, 
and 6.9 percent in the CAUC population, as compared with 
the published reports of 9.5 percent in all populations in the 
U.S.8 Within the Diego blood group system, the phenotypes 
of Di(a+b+) and Di(a+b–) for the HISP population had a 
prevalence of 6.2 percent and 0.3 percent, as compared with 
the published CAUC and black reports of less than 0.1 percent 
and less than 0.01 percent, respectively. Within the Lutheran 
blood group system, the phenotype Lu(a–b+) for the HISP 
population had a prevalence of 97.4 percent compared with the 
published report of 92.4 percent, yet there was a decrease of 
the Lu(a+b+) phenotype (2.7%) compared with the published 
(7.4%). Within the black population, the Dombrock blood 
group system phenotype combination of Do(a+b–)Hy+Jo(a+) 
was 8.0 percent, Do(a+b+)Hy+Jo(a+) was 40.3 percent, and 
Do(a–b+)Hy+Jo(a+) was 50.7 percent as compared with 
published reports of 11 percent, 44 percent, and 45 percent, 
respectively. The South Texas CAUC population phenotype 
prevalence was comparable with the published reports of the 
same ethnicity for those phenotypes (as seen in Table 5). 
In Table 6, the antigen prevalence predicted by RBC 
genotyping is compared among black, CAUC, and HISP 
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Table 5. Prevalence of Colton, Diego, Dombrock, Lutheran, Landsteiner-Wiener, and Scianna blood group phenotypes: comparison of 




South Texas donors Published reports South Texas donors Published reports South Texas donors
N Prevalence (%) Prevalence (%) N Prevalence (%) Prevalence (%) N Prevalence (%)
Colton Co(a+b+) 26 3.3 9.5* 123 6.9 9.5* 45 2.9
Co(a+b–) 770 96.6 90* 1666 93.1 90* 1535 97.1
Co(a–b+) 1 0.1 0.5* 1 0.1 0.5* 1 0.1
Diego Di(a+b+) 2 0.3 <0.1 7 0.4 <0.1 98 6.2
Di(a+b–) 1 0.1 <0.01 0 0.0 <0.01 4 0.3
Di(a–b+) 785 99.6 >99.9 1765 99.6 >99.9 1473 93.5
Dombrock Do(a+b+) Hy+ Jo(a+) 318 40.3 44 856 48.1 49 727 46.4
Do(a+b+) Hy+ Jo(a–) 4 0.5 RARE 0 0.0 None 0 0.0
Do(a+b–) Hy+ Jo(a+) 63 8.0 11 270 15.2 18 227 14.5
Do(a+b–) Hy+ Jo(a–) 3 0.4 RARE 0 0.0 None 0 0.0
Do(a–b+) Hy+ Jo(a+) 402 50.7 45 654 36.7 33 613 39.1
Do(a–b+) Hy– Jo(a–) 1 0.1 RARE 0 0.0 None 0 0.0
Lutheran Lu(a+b+) 37 4.6 7.4† 101 5.6 7.4† 42 2.7
Lu(a+b–) 0 0.0 0.2† 3 0.2 0.2† 0 0.0
Lu(a–b+) 761 95.4 92.4† 1687 94.2 92.4† 1540 97.4
Landsteiner-
Wiener
LW(a+b+) 1 0.1 3† 9 0.5 3† 4 0.3
LW(a+b–) 787 99.9 97† 1781 99.4 97† 1578 99.8
LW(a–b+) 0 0.0 RARE† 1 0.1 RARE† 0 0.0
Scianna SC:1,2 1 0.1 1 5 0.3 0 1 0.1
SC:1,–2 792 99.9 99 1782 99.7 100 1581 99.9
CAUC = Caucasian; HISP = Hispanic.
*All populations. 
†Most populations.
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populations of South Texas donors based on the Hardy-
Weinberg equilibrium. As would be expected, for the Kell blood 
group system, the prevalence of K in the CAUC population 
(4.3%) was higher than that in the black (1.3%) or HISP 
(1.6%) populations. There was a significant increase (10.3%) 
in the predicted prevalence of Jsa in the black population as 
compared with 0.22 percent in the CAUC and 0.67 percent 
in the HISP populations. In the Colton blood group system, 
there was an increased predicted prevalence of Cob (3.5%) in 
the CAUC population, whereas predicted prevalence of only 
1.8 percent and 1.5 percent were observed with the black 
and HISP populations, respectively. In the Kidd blood group 
system, differences in prevalence were evident with Jka at 73.8 
percent for black, but only 50.9 percent and 49.4 percent for 
CAUC and HISP, respectively. There was a significant increase 
in prevalence of Dia at 3.4 percent in the HISP population as 
compared with 0.3 percent in the black and 0.2 percent in the 
CAUC populations.
Discussion
RBC transfusions can save a patient’s life; however, this life-
saving component can also have adverse effects in the patient. 
For example, it can cause shortened RBC survival, leading to 
the increased need for blood transfusion. This step may cause 
iron overload in selected individuals.9 Transfusions can cause 
DHTR, hyperhemolysis syndrome, episodes of pain, acute 
chest syndrome, acute renal failure, chronic positive direct 
antiglobulin test, and development of warm autoantibodies.10 
Patients who are transfused with more than 10 units of 
RBCs have a higher rate of becoming alloimmunized than 
those who are transfused with fewer than 10 units.11,12 The 
rate of alloimmunization is as high as 43 percent in patients 
with SCD, with antibodies to antigens in the Rh and Kell 
blood group systems being the most frequently identified.9,13 
Antibodies to C and E are identified over two-thirds of the 
time.10 Moreover, the U.S. Food and Drug Administration 
reported five transfusion-related fatalities in the category of 
Table 6. Hardy–Weinberg equilibrium two-allele frequency calculations in the South Texas donors
Black CAUC HISP
Kell Phenotype* K+k– K+k+ K–k+ K+k– K+k+ K–k+ K+k– K+k+ K–k+
H-W freq 0.02 2.40 97.51 0.19 8.35 91.46 0.03 3.18 96.80
Frequency† K = 1.25, k = 98.75 K = 4.36, k = 95.64 K = 1.61, k = 98.39
Phenotype* Js(a+b–) Js(a+b+) Js(a–b+) Js(a+b–) Js(a+b+) Js(a–b+) Js(a+b–) Js(a+b+) Js(a–b+)
H-W freq 1.05 18.39 80.56 0.00 0.45 99.55 0.00 1.34 98.66
Frequency† Jsa = 10.25, Jsb = 89.75 Jsa = 0.22, Jsb = 99.78 Jsa = 0.67, Jsb = 99.33
Phenotype* Kp(a+b–) Kp(a+b+) Kp(a–b+) Kp(a+b–) Kp(a+b+) Kp(a–b+) Kp(a+b–) Kp(a+b+) Kp(a–b+)
H-W freq 0.01 2.27 97.72 0.01 2.12 97.86 0.00 1.2 98.7
Frequency† Kpa = 1.15, Kpb = 98.85 Kpa = 1.07, Kpb = 98.93 Kpa = 0.64, Kpb = 99.3
Colton Phenotype* Co(a+b–) Co(a+b+) Co(a–b+) Co(a+b–) Co(a+b+) Co(a–b+) Co(a+b–) Co(a+b+) Co(a–b+)
H-W freq 96.52 3.45 0.03 93.14 6.74 0.12 97.05 2.93 0.02
Frequency† Coa = 98.24, Cob = 1.76 Coa = 96.51, Cob = 3.49 Coa = 98.51, Cob = 1.49
Landsteiner-
Wiener
Phenotype* LW(a+b–) LW(a+b+) LW(a–b+) LW(a+b–) LW(a+b+) LW(a–b+) LW(a+b–) LW(a+b+) LW(a–b+)
H-W freq 99.80 0.13 0.00 99.39 0.61 0.00 99.75 0.25 0.00
Frequency† LWa = 99.94, LWb = 0.06 LWa = 99.6, LWb = 0.31 LWa = 99.87, LWb = 0.13
Kidd Phenotype* Jk(a+b–) Jk(a+b+) Jk(a–b+) Jk(a+b–) Jk(a+b+) Jk(a–b+) Jk(a+b–) Jk(a+b+) Jk(a–b+)
H-W freq 54.47 38.66 6.86 25.59 49.99 24.42 24.43 49.99 25.57
Frequency† Jka = 73.81, Jkb = 26.19 Jka = 50.59, Jkb = 49.41 Jka = 49.43, Jkb = 50.57
Diego Phenotype* Di(a+b–) Di(a+b+) Di(a–b+) Di(a+b–) Di(a+b+) Di(a–b+) Di(a+b–) Di(a+b+) Di(a–b+)
H-W freq 0.00 0.51 99.49 0.00 0.39 99.01 0.11 6.50 93.38
Frequency† Dia = 0.25, Dib = 99.75 Dia = 0.2, Dib = 99.8 Dia = 3.37, Dib = 96.63
Lutheran Phenotype* Lu(a+b–) Lu(a+b+) Lu(a–b+) Lu(a+b–) Lu(a+b+) Lu(a–b+) Lu(a+b–) Lu(a+b+) Lu(a–b+)
H-W freq 0.05 4.53 95.42 0.09 5.80 94.11 0.02 2.62 97.36
Frequency† Lua = 2.32, Lub = 97.68 Lua = 2.99, Lub = 97.01 Lua = 1.33, Lub = 98.67
CAUC = Caucasian; HISP = Hispanic; H-W = Hardy–Weinberg; freq = frequency.
*Genotype-predicted antigen phenotype.
†Frequency of genotype-predicted antigen phenotype.
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HTR (non-ABO) for fiscal year 2013.14 These included the 
following antibody specificities: anti-c, anti-E, anti-Jka, anti-
Jkb, and anti-K. 
It has been documented that providing phenotypically 
matched blood drastically decreases the alloimmunization 
rate.15 One study showed dramatic decreases of alloimmu-
nization—from 35 percent to 0 percent—in patients with 
SCD who received extended phenotype-matched blood (Rh, 
Kell, MNS, Duffy, and Kidd blood group systems). A second 
study showed a decrease from 34 percent to 7 percent.16 
Another study provided blood from donors ethnically similar 
to the recipients; this was based on antigen prevalence within 
black and Caucasian populations. Results showed a higher 
probability of finding an extended phenotype-matched donor 
for a patient with SCD in the black donor population (93%) 
than in the Caucasian donor population (7%).10,17 In the black 
population, many RH alleles encoding for many complex 
phenotype variants have been described; this may explain why 
one cohort study demonstrated that using limited phenotype 
matching did not show a decrease in alloimmunization rate 
with Rh antibodies in this population.16 However, providing 
blood that is genotypically matched instead of serologically 
phenotyped for the Rh blood system has been found to further 
decrease alloimmunization rates.5,10,18
The lack of standardization in providing limited and/or 
extended phenotype-matched donor units among transfusion 
services is attributed to pressures of cost management of 
transfusion therapy for SCD.19 One cohort study compared the 
cost of antigen-matching strategies for (1) matching only those 
patients with SCD who have developed or have a history of 
antibodies and (2) prospective matching regardless of antibody 
development.13 To provide limited or extended matching, mass 
screening of blood donors using genotyping methods would 
need to be performed on an ongoing basis. Donor genotyping 
can not only increase antigen-negative inventory, but can 
also identify rare donors who lack high-prevalence antigens. 
Furthermore, the use of other RH DNA analysis testing 
kits can manage RH typing variations, but will not resolve 
ABO discrepancies or find weak D that would otherwise 
not be identified by conventional serologic screening.20–22 
There are some limitations of genotyping—for example, not 
being able to accurately predict donors with less common 
silencing mutations, causing the phenotype to be predicted 
as expressed, thus a false-positive for the antigen; the most 
common silencing mutation available in most commercial RBC 
genotyping panels is the FY GATA mutation.22–24 In addition, 
DNA testing turnaround time takes hours, not all the alleles 
are known for each ethnic group, the cost between genotyping 
and serologic phenotyping varies, and genotype and serologic 
results may not agree.22–24
In conclusion, this is the first study to determine the 
prevalence of various RBC phenotypes among the South Texas 
blood donor population using a genotyping methodology. 
There is limited availability of published data for blood 
group phenotype prevalence for Hispanics; therefore, this 
study can establish a benchmark. This valuable information 
provides antigen-negative prevalence within the three major 
ethnic groups (black, CAUC, HISP) of South Texas blood 
donors. Because frequently transfused patients have higher 
probability of developing antibodies, knowledge of antigen 
prevalence in different ethnicities can assist in complex 
antibody identification cases and can help determine the most 
appropriate antigen-matched blood product to provide. Given 
that alloimmunization occurs in up to 43 percent of patients 
with SCD, providing limited and/or extended matching to all 
may be a challenge in the South Texas population. Creating 
effective algorithms to genotype black, CAUS, and HISP 
blood donors can potentially increase the rare donor database. 
This step can supply adequate antigen-negative blood to the 
unique diversity of South Texas patients, possibly preventing 
alloimmunization and supporting those patients who are 
already alloimmunized. 
Based on the data collected from South Texas donors, our 
donor center will select groups A and O donors who are black, 
instead of the current practice of randomly selecting black 
donors for further genotyping. Black donors have a higher 
probability of phenotyping as R0r, Fy(a–b–), and Jk(a+b–). 
Selecting black donors will decrease alloimmunization in our 
patients with sickle cell disease as well as ensure an adequate 
supply for patients of this ethnicity who develop alloantibodies, 
thus decreasing the delay in finding compatible blood. Also, 
specifically selecting Hispanic donors will increase the R1R1, 
R2R2, Fy(a+b–), and Jk(a–b+) rare donor inventory, providing 
adequate rare blood to HISP, black, and CAUC populations. In 
addition, there is a higher probability in finding rare blood that 
is Di(a+b–), given that the prevalence of Di(b+) donors is 96.6 
percent in Hispanics. Alloanti-Dib is clinically significant, and 
is known to cause mild to delayed transfusion reactions. Using 
this algorithm to genotype South Texas donor populations 
should start to establish an adequate rare donor pool to supply 
rare blood to this diverse population. This step also challenges 
other Texas and diverse geographically located donor centers to 
publish their phenotype prevalences and establish appropriate 
algorithms to maintain adequate rare blood supply.
L.I. Aranda et al.
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